CHIPSA and North Beach Clinic Launch new Coley’s CPG Treatment (Exclusive)
The U.S. Food and Drug Administration (FDA) currently has several ongoing trials testing immunotherapy cancer treatments like CPG and checkpoint inhibitor drugs. In fact, the internet was up in arms last year when Stanford University doctors cured 87 out of 90 mice with a “vaccine” that stimulated the immune system to attack cancerous cells. It was described as a “breakthrough treatment,” but the truth is, a very similar treatment was already being used to treat human patients at a hospital in Mexico.
CHIPSA Hospital, which is located in Tijuana, is an integrative immunotherapy hospital that offers patients access to several cutting-edge therapies and nutritional regimens. Many of our treatments have been long discounted by mainstream medical communities, only to be later approved and legitimized in the United States. CPG is one of them.
Dr. Anton Escobedo, the hospital’s medical director, said the clinical study was actually music to his hears. “When the study came out,” he said, “I was pleased to see they were using CPG. We have a lot of experience with a form of CPG so we weren’t surprised to see it work well in combination with checkpoint inhibitors. We love when science proves what we’re doing is right. 10 years ago, they wouldn’t even acknowledge it.”
So what exactly is CPG?
CPG is one of the main drivers of a treatment protocol called Coley’s toxins. Coley’s toxins was discovered in 1891 by Dr. William Coley, a surgeon at Memorial Hospital, which is now known as Sloan Kettering in New York City. In one of his studies, Coley discovered that the only surviving patient of a sarcoma had contracted a bacterial infection that was so advanced he almost died. But after overcoming the infection, the patient’s cancer was completely gone. It soon became clear to Coley that infection stimulated the immune system so much that it also began to eradicate disease.
Coley then developed live bacteria “vaccines” to to give to cancer patients in the hopes that their bodies would also fight off the cancer. He had several patients go into remission after the live vaccine, and even more when he changed the bacteria from live to “dead” to reduce the number of patients dying from infection.
Scientists discovered CPG in the 1990s and found it to be a strong driver of the immune system. Early FDA trials of CPG showed some impressive patient responses, but in the end, the trial failed. Now, 10 years later, there are multiple trials testing CPG and checkpoint inhibitor immunotherapy. It seems that CPG might be the key to getting more patients to respond to checkpoint inhibitor drugs.
CHIPSA has been using Coley’s fluid since 1996. There are multiple TLR pathways that Coley’s fluid activates, and many of them aren’t well understood, but one that has been heavily studied is CPG.
“In many ways, we have been on the sidelines cheering these studies on,” said Escobedo. “It’s a treatment we understand well. But the problem with trials is that they don’t leave much room for a doctor to be a doctor. They are rigorous scientific studies, and rigorous scientific studies aren’t doing what’s best for every individual patient. That’s one of the ways we’re much different at CHIPSA.”
While researchers have been working on trials with CPG in the United States, CHIPSA has been treating patients with Coley’s toxins in combination with checkpoint inhibitors like Opvido and Keytruda. We now have a new formulation called Coley’s CPG that is made from streptococcus pyogenes. The new formula has the potential to create an even greater response for CHIPSA patients using a combination approach.
What’s unique about CHIPSA is that we use both science backed alternative and conventional treatments, making us an integrative hospital. One method we use frequently is low dose chemotherapy in combination with immunotherapy.
Low dose chemotherapy has been shunned for years by the mainstream medical community. Most oncologists argue that it’s a waste to use chemotherapy at such low doses. But CHIPSA had other ideas in mind.
What if the chemotherapy was actually notifying the immune system that cancer was present in the body? And what if it were to be used in combination with Coley’s CPG, checkpoint inhibitors, and Apatone? This way, cancer can be treated with less toxic chemotherapy and more natural immunity.
“Our approach is common sense,” said Escobedo. “We are looking to combine the best in cutting-edge therapy with the things we know have worked for years. This is truly an exciting time for us at CHIPSA because we have many companies completing trials with variations of different treatments that we offer. We are able to use the data to make adjustments. And nobody understands the combinations the way we do. I suspect it will take the U.S. another 10 years to catch up.”
These approaches are in many ways common sense. CHIPSA combines the best of all modalities, which includes a focus on nutrition, gut health, mental and emotional health, and cutting-edge treatments like checkpoint inhibitors, Coley’s CPG, and targeted low-dose chemotherapy. This true combination approach gives patients the best possible chance to heal.